Eve & Co has been approved by Health Canada an amendment to the licence of its wholly-owned subsidiary, Natural MedCo, permitting the use of a 7,300 square foot area (“Processing Area 2“) as eleven additional processing rooms. "Processing Area 2 enables the Company to continue its production ramp-up to supply cannabis markets in Canada and abroad under its European Union Certificate of Good Manufacturing Practice from the Government of Upper Bavaria, Germany," the team with the company explains.
“We are very pleased to have received Health Canada’s approval for our additional processing area. This is an integral step in supporting our 780,000 square foot flowering room expansion and production ramp-up. With this approval, we intend to ramp-up production over the next two quarters which will give us the ability to become a significant supplier to the Canadian and global cannabis markets(1),” said Melinda Rombouts, President and CEO of Eve & Co.
"Processing Area 2 provides immediate licensed capacity to facilitate additional social distancing measures for the Company during the COVID-19 pandemic."
"The Company anticipates production capacity will increase to approximately 50,000 kgs annually, allowing Eve & Co to introduce a number of value-added products to the Canadian market under its female-focused “Eve” brand while continuing to build and execute on its international program," they conclude.
For more information:
Eve & Co.
+1 (833) EVE-CANN
[email protected]
evecannabis.ca